Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
